Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Introduction: Immune thrombocytopenia (ITP) secondary to durvalumab, a programmed cell death ligand 1 inhibitor, is a rare but clinically significant immune-related adverse event. Herein, we present 2 patients with cholangiocarcinoma who developed ITP immediately post-yttrium-90 radioembolization (Y...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Maaz Khan Afghan, Areeb Lutfi, Fatima Qadri, Sahrish Khan, Sana Javaid, Brian Michael Currie, Juan Pablo Rocca, Benjamin Samstein, Erika Hissong, Pashtoon Murtaza Kasi
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Karger Publishers 2024-10-01
Edice:	Case Reports in Oncology
Témata:	cholangiocarcinoma durvalumab immune thrombocytopenia yttrium-90
On-line přístup:	https://beta.karger.com/Article/FullText/541550
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!